AstraZeneca, Broad Institute collaborate to develop anti-infective agents
Pursuant to the agreement, screening and hit-to-lead chemistry will take place in the Broad’s Chemical Biology Platform and AstraZeneca will optimize, develop and commercialize potential compounds from identified,